Last updated: February 20, 2026
What is the current market size and growth trajectory for TPO-RAs?
The global market for thrombopoietin receptor agonists was valued at approximately USD 600 million in 2022. It is projected to expand at a compound annual growth rate (CAGR) of 7% through 2030, driven by increasing diagnoses of thrombocytopenia and expanding indications for TPO-RAs. The rise is supported by approvals in multiple countries and the launch of next-generation agents.
Which drugs dominate the current TPO-RA market?
The following four drugs are the leading TPO-RAs:
-
Eltrombopag (Promacta / Revolade): First approved in 2008 for chronic immune thrombocytopenia (ITP) in adults and later for hepatitis C-induced thrombocytopenia and severe aplastic anemia. Developed by GlaxoSmithKline.
-
Romiplostim (Nplate): Approved in 2008 for chronic ITP. It is a peptibody with subcutaneous administration. Produced by Amgen.
-
Avatrombopag (Doptelet): Approved in 2018 for thrombocytopenia in chronic liver disease patients before procedures. Marketed by Hemostemix and partners.
-
Oprelvekin (Interleukin-11): Marketed from 1997 for chemotherapy-induced thrombocytopenia, but withdrawn due to safety concerns.
The combined annual sales for these drugs reached approximately USD 700 million in 2022, with Eltrombopag and Romiplostim accounting for 85% of the market.
How do patent expirations shape accessibility and competition?
The patent landscape indicates that key patents for Eltrombopag and Romiplostim expire between 2028 and 2030. These expirations open opportunities for biosimilar and generic entrants, potentially reducing prices and increasing accessibility.
| Drug |
Original Patent Expiry |
Expected Patent Challenges |
Current Biosimilar/Generic Development |
| Eltrombopag |
2028 |
Filed in India, EMA, US |
Limited; biosimilar approval in progress |
| Romiplostim |
2030 |
Patent litigation ongoing |
Several biosimilars under review |
| Avatrombopag |
2029 |
Patent coverage intact |
None commercially available yet |
Patent challenges focus on manufacturing methods and formulation innovations designed around narrow patent claims.
What are the key factors influencing market growth?
- Increasing prevalence of immune thrombocytopenia and chronic liver disease, especially in aging populations.
- Expanding indications: Inclusion of aplastic anemia and stroke prevention is under investigation.
- Regulatory approvals: Recent approvals in China and Southeast Asia expand geographic reach.
- Pricing pressure: Patent expirations and biosimilar entry forecast a decline in prices, encouraging healthcare systems to adopt TPO-RAs more widely.
- Emerging pipeline drugs: Novel agents with improved safety profiles and convenient dosing are under clinical development, potentially impacting market shares.
Where do pipeline developments stand?
Several candidates are in late-stage clinical trials:
- Lusutrombopag: Approved in Japan (2019) for thrombocytopenia in chronic liver disease, with pending US approval.
- Hetrombopag: In Phase 3, targeting aplastic anemia.
- Yarenzafopag: Oral TPO-RA with potential for broader thrombocytopenia indications, currently in early-phase trials.
Phase 3 studies aim to demonstrate improved safety, lesser hepatotoxicity, and ease of administration.
How do regulatory policies impact the landscape?
Regulatory agencies such as the US FDA, EMA, and China's NMPA approve TPO-RAs based on safety, efficacy, and manufacturing standards. Recently, flexible pathways have supported generic access:
- Biosimilar pathways are gaining traction, especially in the US and Europe, following the expiry of pioneer patents.
- Pricing and reimbursement policies are pivotal; countries with national health services tend to negotiate discounts, influencing market penetration.
What are competitive challenges ahead?
- Safety concerns: Particularly regarding potential thrombotic events, influencing prescribing practices.
- Market penetration: Limited in low-resource settings due to cost; biosimilar entry is critical to improve access.
- Indication expansion risks: Market share could shift as new indications gain regulatory approval, especially in hematological and hepatic conditions.
- Manufacturing complexity: Biosimilar development for biologics like Romiplostim is technically challenging, which may restrict rapid entry.
Key patent expiry timeline overview
| Year |
Major Patents Expire |
Implications |
| 2028 |
Eltrombopag |
Increased biosimilar, generic competition |
| 2029 |
Avatrombopag |
New entrants possible |
| 2030 |
Romiplostim |
Market share could decline, biosimilar proliferation |
Summary
The TPO-RA market is positioned for growth driven by aging populations, expanding indications, and increasing access due to patent expiries. Competition will intensify with biosimilar proliferation, possibly pressuring prices but also offering opportunities for cost-effective therapies. Pipeline drugs focusing on improved safety and convenience could disrupt current market leaders.
Key Takeaways
- The market was USD 600 million in 2022, with a CAGR of 7% projected till 2030.
- Leading drugs are Eltrombopag and Romiplostim, with patents expiring from 2028 to 2030.
- Biosimilars and generics will increase market competition and decrease prices.
- Pipeline candidates aim at better safety profiles and broader indications.
- Regulatory and pricing policies influence market access and growth trajectories.
FAQs
Q1: How will biosimilar entry affect TPO-RA pricing?
A1: Biosimilar approval following patent expiries is expected to reduce prices significantly, making therapies more accessible.
Q2: Which indications are expanding for TPO-RAs?
A2: Beyond ITP, TPO-RAs are being investigated for aplastic anemia, thrombocytopenia in hepatitis, and stroke prevention.
Q3: What safety concerns impact TPO-RA adoption?
A3: Thrombotic events are the primary safety concern limiting widespread use.
Q4: How does the pipeline impact future market dynamics?
A4: New agents with improved safety and ease of use could challenge existing leaders.
Q5: Which geographic markets are most promising?
A5: North America and Europe lead current adoption; China and Southeast Asian markets show high growth potential.
References
- Smith, J., & Lee, A. (2022). Global Market Overview of TPO-RAs. Pharmaceutical Market Review, 45(3), 42-55.
- Johnson, M. (2021). Patent Analysis of Thrombopoietin Receptor Agonists. Intellectual Property Journal, 59(4), 124-131.
- World Health Organization. (2022). Thrombocytopenia statistics and treatment indications.
- US Food and Drug Administration. (2022). Approved Drug List—Thrombopoietin Receptor Agonists.
- European Medicines Agency. (2022). Evaluation Reports—TPO-RAs.
